Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
Of those vehicles, the ones that closed a merger.
Announced but not closed, and still hunting.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 liquidated — weigh against the wins.
1 vehicle on file, newest listing first
Thomas Leggett ​ ​ ​ ​ 44 ​ ​ ​ Director ​ Clive Patience ​ ​ ​ ​ 57 ​ ​ ​ Director ​ Peter Kolchinsky, Ph.D. , 44, has been our Chief Executive Officer and board Chairman since July 2020. Mr. Kolchinsky has served as a Portfolio Manager and Managing Partner of RA Capital Management, L.P. since September 2004. Mr. Kolchinsky is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He serves as a member of the board of directors of Icosavax, Inc., Therapeutics Acquisition Corp., Sojournix, Inc., Freenome Holdings, Inc., Wave Life Sciences Ltd. and Forma Therapeutics Holdings, Inc. He previously served as a member of the board of directors of Synthorx, Inc. and Dicerna Pharmaceuticals, Inc.
This record is keyed to SEC CIK 0001774690 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 73 institutional-holder rows on these vehicles, under 32 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.